Editor Rebekah Jordan spoke to Kevin Kreutter, Ph.D., senior vice president, Drug Discovery, Empress Therapeutics about how the company is using AI to analyse genetic data, to accelerate and refine small molecule drug discovery.
Sonrai is working to bring its innovative cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH), enabling vast and complex data for more meaningful insights.
Bioptimus announced that its H-optimus-0 foundation model is now integrated into Proscia’s Concentriq Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development.
Renato Rjavec, ArisGlobal, discusses how generative AI (GenAI) technology is transforming everyday regulatory and safety processes, thanks to its ability to summarise key insights and findings from across huge, diverse bodies of content and data.
Life sciences manufacturers continuously strive for accelerated launch, increased capacity for in-demand medicine, enhanced security of supply and improved sustainability.
Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
Ramesh Ramani and RaviKanth Valigari, AI experts at ArisGlobal, explore how large language model-enabled AI will sharpen drug safety & regulatory practice.
Dr Dror Kolodkin Gal, founder of image checking tool, Proofig AI, explores the challenges faced when reviewing Western blot images in pharmaceutical research.
Life Sciences data expert Dr Alexander Jarasch on the learnings other R&D teams can gain from the use of graphs at the Institut de Recherches Servier for our latest EPM Online Insight.
There is a real opportunity for AI to maximise Life Sciences companies’ investment in regulatory data management. ArisGlobal’s Agnes Cwienczek & Renato Rjavec set out practical examples of AI and Generative AI delivering tangible benefits.
